{"id":"NCT01603615","sponsor":"Allergan","briefTitle":"BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity","officialTitle":"BOTOX® Treatment in Pediatric Upper Limb Spasticity: Open-label Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-30","primaryCompletion":"2018-09-03","completion":"2018-09-03","firstPosted":"2012-05-22","resultsPosted":"2019-08-21","lastUpdate":"2019-08-21"},"enrollment":220,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pediatrics","Muscle Spasticity","Cerebral Palsy","Stroke"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum Toxin Type A","otherNames":["BOTOX® OnabotulinumtoxinA"]}],"arms":[{"label":"BOTOX®","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.","primaryOutcome":{"measure":"Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE)","timeFrame":"From first dose of study drug up to 12 weeks post last dose (Up to 60 weeks)","effectByArm":[{"arm":"BOTOX®","deltaMin":58.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":48,"countries":["United States","Canada","Hungary","Philippines","Poland","Russia","South Korea","Thailand","Turkey (Türkiye)"]},"refs":{"pmids":[],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":213},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Cough"]}}